CCM
BPMC

CAAS Capital Management’s Blueprint Medicines BPMC Stock Holding History

CAAS Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,000
Closed -$526K – 723
2022
Q4 		$526K Buy
+12,000
New +$575K 0.03% 396
2021
Q1 		– Sell
-10,000
Closed -$1.12M – 1168
2020
Q4 		$1.12M Buy
+10,000
New +$1.05M 0.01% 592

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAAS Capital Management's BPMC Position: Q1 2023 in Review

CAAS Capital Management sold out of Blueprint Medicines (BPMC) in Q1 2023, closing a stake of 12,000 shares — an estimated $526K sold.

CAAS Capital Management first reported a position in BPMC in Q4 2020 and held it in 2 quarters. The position peaked at $1.12M in Q4 2020. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2023.

  • CAAS Capital Management reported no remaining Blueprint Medicines position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 12,000 Blueprint Medicines shares in Q1 2023, an estimated $526K.
  • CAAS Capital Management first reported a position in Blueprint Medicines in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's Blueprint Medicines position peaked at $1.12M in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.